Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 1
2013 2
2014 1
2015 2
2016 3
2017 2
2018 4
2019 9
2020 2
2021 1
2022 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of the "Burgenland PREvention trial of colorectal cancer Disease with ImmunologiCal Testing" (B-PREDICT)-a population-based colorectal cancer screening program.
Brezina S, Leeb G, Baierl A, Gräf E, Hackl M, Hofer P, Lang H, Klein M, Mach K, Schwarzer R, Wlassits W, Püspök A, Gsur A. Brezina S, et al. Among authors: hofer p. BMC Gastroenterol. 2024 Apr 30;24(1):149. doi: 10.1186/s12876-024-03242-7. BMC Gastroenterol. 2024. PMID: 38689217 Free article.
Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases.
Mrak D, Kartnig F, Sieghart D, Simader E, Radner H, Mandl P, Göschl L, Hofer P, Deimel T, Gessl I, Kain R, Winkler S, Smolen JS, Perkmann T, Haslacher H, Aletaha D, Heinz LX, Bonelli M. Mrak D, et al. Among authors: hofer p. J Autoimmun. 2023 Feb;135:102981. doi: 10.1016/j.jaut.2022.102981. Epub 2022 Dec 22. J Autoimmun. 2023. PMID: 36706534 Free PMC article.
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls.
Kartnig F, Mrak D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Hommer N, Mayer M, Hofer P, Hummel T, Deimel T, Geßl I, Puchner A, Kerschbaumer A, Thalhammer R, Handisurya A, Kain R, Winkler S, Smolen JS, Stiasny K, Perkmann T, Haslacher H, Aberle JH, Aletaha D, Heinz LX, Sieghart D, Bonelli M. Kartnig F, et al. Among authors: hofer p. Ann Rheum Dis. 2023 Feb;82(2):292-300. doi: 10.1136/ard-2022-222682. Epub 2022 Sep 15. Ann Rheum Dis. 2023. PMID: 36109141 Clinical Trial.
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial.
Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Koblischke M, Hommer N, Wagner A, Mayer M, Schubert L, Hartl L, Kozbial K, Hofer P, Kartnig F, Hummel T, Kerschbaumer A, Deimel T, Puchner A, Gudipati V, Thalhammer R, Munda P, Uyanik-Ünal K, Zuckermann A, Novacek G, Reiberger T, Garner-Spitzer E, Reindl-Schwaighofer R, Kain R, Winkler S, Smolen JS, Stiasny K, Fischer GF, Perkmann T, Haslacher H, Zeitlinger M, Wiedermann U, Aberle JH, Aletaha D, Heinz LX, Bonelli M. Mrak D, et al. Among authors: hofer p. Nat Commun. 2022 Sep 12;13(1):5362. doi: 10.1038/s41467-022-33036-y. Nat Commun. 2022. PMID: 36097029 Free PMC article. Clinical Trial.
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study.
Mrak D, Simader E, Sieghart D, Mandl P, Radner H, Perkmann T, Haslacher H, Mayer M, Koblischke M, Hofer P, Göschl L, Kartnig F, Deimel T, Kerschbaumer A, Hummel T, Kornek B, Thalhammer R, Stiasny K, Winkler S, Smolen JS, Aberle JH, Aletaha D, Heinz LX, Bonelli M. Mrak D, et al. Among authors: hofer p. Ann Rheum Dis. 2022 Dec;81(12):1750-1756. doi: 10.1136/ard-2022-222579. Epub 2022 Aug 17. Ann Rheum Dis. 2022. PMID: 35977809
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
Bonelli M, Mrak D, Tobudic S, Sieghart D, Koblischke M, Mandl P, Kornek B, Simader E, Radner H, Perkmann T, Haslacher H, Mayer M, Hofer P, Redlich K, Husar-Memmer E, Fritsch-Stork R, Thalhammer R, Stiasny K, Winkler S, Smolen JS, Aberle JH, Zeitlinger M, Heinz LX, Aletaha D. Bonelli M, et al. Among authors: hofer p. Ann Rheum Dis. 2022 May;81(5):687-694. doi: 10.1136/annrheumdis-2021-221558. Epub 2022 Jan 13. Ann Rheum Dis. 2022. PMID: 35027397 Clinical Trial.
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Hofer P, Perkmann T, Haslacher H, Thalhammer R, Winkler S, Blüml S, Stiasny K, Aberle JH, Smolen JS, Heinz LX, Aletaha D, Bonelli M. Mrak D, et al. Among authors: hofer p. Ann Rheum Dis. 2021 Oct;80(10):1345-1350. doi: 10.1136/annrheumdis-2021-220781. Epub 2021 Jul 20. Ann Rheum Dis. 2021. PMID: 34285048
Personalized medicine in Austria: expectations and limitations.
Pot M, Brehme M, El-Heliebi A, Gschmeidler B, Hofer P, Kroneis T, Schirmer M, Schumann S, Prainsack B. Pot M, et al. Among authors: hofer p. Per Med. 2020 Nov;17(6):423-428. doi: 10.2217/pme-2020-0061. Epub 2020 Oct 7. Per Med. 2020. PMID: 33026295 Free article. No abstract available.
36 results